Indications & Goals - The Long Game
- Primary Goal: Prevent recurrence of manic and depressive episodes, enabling long-term mood stability (euthymia).
- Indications for lifelong maintenance:
- After 1 severe manic episode (e.g., requiring hospitalization, psychotic features).
- After ≥2 confirmed bipolar mood episodes.
- Patients with a strong family history of severe bipolar disorder.
⭐ The risk of recurrence without maintenance therapy is extremely high, approaching >90% within 5 years after a manic episode.
First-Line Mood Stabilizers - The Classics
- Core agents for long-term prevention of manic and depressive episodes. Choice depends on the patient's predominant polarity (mania vs. depression) and side effect profile.
| Agent | Primary Efficacy | Key Adverse Effects (AEs) | Monitoring Pearls |
|---|---|---|---|
| Lithium | Mania prevention | Tremor, polyuria (nephrogenic DI), hypothyroidism, teratogen (Ebstein anomaly) | Therapeutic window: 0.6-1.2 mEq/L. Check TSH, BUN/Cr, Ca²⁺. 📌 LMNOP: Lithium, Movement, Nephrogenic DI, O (hypOthyroidism), Pregnancy problems. |
| Valproate | Mania prevention | Hepatotoxicity, pancreatitis, thrombocytopenia, alopecia, significant weight gain. Highly teratogenic (neural tube defects). | Check LFTs, CBC (platelets). |
| Lamotrigine | Depression prevention | ⚠️ Stevens-Johnson Syndrome (SJS), benign rash. | 💡 Slow dose titration is critical to minimize SJS risk. Valproate ↑ lamotrigine levels. |
Adjuncts & Alternatives - The New Guard
Second-generation antipsychotics (SGAs) are crucial, especially for patients with psychosis or when traditional mood stabilizers are insufficient/poorly tolerated. Many are FDA-approved for maintenance monotherapy.
- Key Agents: Aripiprazole, Olanzapine, Quetiapine, Risperidone (long-acting injection), Ziprasidone.
⭐
Olanzapine and Clozapine carry the highest risk of metabolic side effects (weight gain, dyslipidemia, hyperglycemia) - a major consideration for long-term use.
Maintenance Agent Selection Flowchart
Safety & Monitoring - The Watchful Eye
- Long-term vigilance is key to prevent toxicity and manage side effects.
| Monitoring Parameter | Lithium | Valproate | Second-Gen Antipsychotics |
|---|---|---|---|
| Baseline | BUN/Cr, TSH, ECG, Ca²⁺, hCG | LFTs, CBC, hCG | Lipids, Glucose/A1c, Wt/BMI |
| Ongoing | Drug Level, BUN/Cr, TSH | LFTs, CBC | Lipids, Glucose/A1c, Wt/BMI |
| Therapeutic Level | 0.6-1.2 mEq/L | 50-125 µg/mL | N/A |
⭐ Lithium-induced nephrogenic diabetes insipidus (polyuria, polydipsia) is a classic, testable side effect from chronic use.
High‑Yield Points - ⚡ Biggest Takeaways
- Lithium is a first-line mood stabilizer for long-term maintenance.
- Valproate is particularly effective for mixed episodes and rapid cycling.
- Lamotrigine is best for preventing bipolar depression but requires slow titration due to SJS risk.
- Second-generation antipsychotics (e.g., quetiapine) can be used as monotherapy or adjuncts.
- AVOID antidepressant monotherapy due to the high risk of inducing mania.
- Regular monitoring of drug levels (Lithium) and side effects is crucial.
Unlock the full lesson and continue reading
Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more
